{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T07:01:04Z","timestamp":1788505264780,"version":"build-2803163510"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T00:00:00Z","timestamp":1763424000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T00:00:00Z","timestamp":1763424000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1007\/s40262-025-01588-z","type":"journal-article","created":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T12:26:44Z","timestamp":1763468804000},"page":"217-228","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["TLD-1, a Novel Liposomal Doxorubicin, in Patients with Solid Tumors: Comparative Pharmacokinetics and Final Results of a Multicenter Phase 1 Study (SAKK 65\/16)"],"prefix":"10.1007","volume":"65","clinical-trial-number":[{"clinical-trial-number":"nct03387917","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-1706-6289","authenticated-orcid":false,"given":"Marian","family":"Klose","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0602-8667","authenticated-orcid":false,"given":"Ilaria","family":"Colombo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katrin","family":"Gobat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6549-8124","authenticated-orcid":false,"given":"Kira-Lee","family":"Koster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9721-3314","authenticated-orcid":false,"given":"Simon","family":"Haefliger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6764-1844","authenticated-orcid":false,"given":"Manuela","family":"Rabaglio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Bastian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Schwitter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ursina","family":"Z\u00fcrrer-H\u00e4rdi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katrin","family":"Eckhardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2265-6559","authenticated-orcid":false,"given":"Stefanie","family":"Hayoz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-3641-6795","authenticated-orcid":false,"given":"Stefan","family":"Halbherr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristiana","family":"Sessa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5485-607X","authenticated-orcid":false,"given":"Robin","family":"Michelet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5936-1877","authenticated-orcid":false,"given":"Anna M.","family":"Mc Laughlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-4993-8744","authenticated-orcid":false,"given":"Dagmar","family":"Hess","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2859-7529","authenticated-orcid":false,"given":"Anastasios","family":"Stathis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"Kloft","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6602-6287","authenticated-orcid":false,"given":"Markus","family":"Joerger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,18]]},"reference":[{"key":"1588_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2165\/00003495-199700544-00003","volume":"54","author":"GN Hortob\u00e1gyi","year":"1997","unstructured":"Hortob\u00e1gyi GN. Anthracyclines in the treatment of cancer. Drugs. 1997;54:1\u20137.","journal-title":"Drugs"},{"key":"1588_CR2","unstructured":"U.S. Food and Drug Administration (FDA). Adriamycin (Doxorubicin Hydrochloride) Injection, USP\u2013FDA Label [Internet]. U.S. Food and Drug Administration; 2010 [cited 2025 Mar 13]. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2010\/050467s070lbl.pdf. Accessed 30 Oct 2025."},{"key":"1588_CR3","doi-asserted-by":"publisher","first-page":"15","DOI":"10.2165\/00003088-198815010-00002","volume":"15","author":"PAJ Speth","year":"1988","unstructured":"Speth PAJ, van Hoesel QGCM, Haanen C. Clinical pharmacokinetics of doxorubicin. Clin Pharmacokinet. 1988;15:15\u201331.","journal-title":"Clin Pharmacokinet"},{"key":"1588_CR4","unstructured":"U.S. Food and Drug Administration (FDA). DOXIL (doxorubicin HCl liposome injection) for intravenous infusion \u2013 FDA Label [Internet]. U.S. Food and Drug Administration; 2007 [cited 2025 Mar 13]. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2007\/050718s029lbl.pdf. Accessed 30 Oct 2025."},{"key":"1588_CR5","first-page":"567","volume":"2","author":"AM Rahman","year":"2007","unstructured":"Rahman AM, Yusuf SW, Ewer MS. Anthracycline-induced cardiotoxicity and the cardiac-sparing effect of liposomal formulation. Int J Nanomed. 2007;2:567\u201383.","journal-title":"Int J Nanomed"},{"key":"1588_CR6","doi-asserted-by":"publisher","first-page":"3585","DOI":"10.1073\/pnas.85.10.3585","volume":"85","author":"RD Olson","year":"1988","unstructured":"Olson RD, Mushlin PS, Brenner DE, Fleischer S, Cusack BJ, Chang BK, et al. Doxorubicin cardiotoxicity may be caused by its metabolite, doxorubicinol. Proc Natl Acad Sci USA. 1988;85:3585\u20139.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1588_CR7","doi-asserted-by":"publisher","first-page":"15851","DOI":"10.1016\/S0021-9258(18)47666-1","volume":"262","author":"RJ Boucek","year":"1987","unstructured":"Boucek RJ, Olson RD, Brenner DE, Ogunbunmi EM, Inui M, Fleischer S. The major metabolite of doxorubicin is a potent inhibitor of membrane-associated ion pumps. A correlative study of cardiac muscle with isolated membrane fractions. J Biol Chem. 1987;262:15851\u20136.","journal-title":"J Biol Chem"},{"key":"1588_CR8","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/0277-5379(82)90060-8","volume":"18","author":"F Olson","year":"1982","unstructured":"Olson F, Mayhew E, Maslow D, Rustum Y, Szoka F. Characterization, toxicity and therapeutic efficacy of adriamycin encapsulated in liposomes. Eur J Cancer Clin Oncol. 1982;18:167\u201376.","journal-title":"Eur J Cancer Clin Oncol"},{"key":"1588_CR9","first-page":"459","volume":"77","author":"A Gabizon","year":"1986","unstructured":"Gabizon A, Meshorer A, Barenholz Y. Comparative long-term study of the toxicities of free and liposome-associated doxorubicin in mice after intravenous administration. J Natl Cancer Inst. 1986;77:459\u201369.","journal-title":"J Natl Cancer Inst"},{"key":"1588_CR10","first-page":"1532","volume":"40","author":"A Rahman","year":"1980","unstructured":"Rahman A, Kessler A, More N, Sikic B, Rowden G, Woolley P, et al. Liposomal protection of adriamycin-induced cardiotoxicity in mice. Cancer Res. 1980;40:1532\u20137.","journal-title":"Cancer Res"},{"key":"1588_CR11","first-page":"4734","volume":"42","author":"A Gabizon","year":"1982","unstructured":"Gabizon A, Dagan A, Goren D, Barenholz Y, Fuks Z. Liposomes as in vivo carriers of adriamycin: reduced cardiac uptake and preserved antitumor activity in mice. Cancer Res. 1982;42:4734\u20139.","journal-title":"Cancer Res"},{"key":"1588_CR12","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1093\/annonc\/mdh097","volume":"15","author":"MER O\u2019Brien","year":"2004","unstructured":"O\u2019Brien MER, Wigler N, Inbar M, Rosso R, Grischke E, Santoro A, et al. Reduced cardiotoxicity and comparable efficacy in a phase IIItrial of pegylated liposomal doxorubicin HCl(CAELYXTM\/Doxil\u00ae) versus conventional doxorubicin forfirst-line treatment of metastatic breast cancer. Ann Oncol. 2004;15:440\u20139.","journal-title":"Ann Oncol"},{"key":"1588_CR13","first-page":"3698","volume":"44","author":"QG van Hoesel","year":"1984","unstructured":"van Hoesel QG, Steerenberg PA, Crommelin DJ, van Dijk A, van Oort W, Klein S, et al. Reduced cardiotoxicity and nephrotoxicity with preservation of antitumor activity of doxorubicin entrapped in stable liposomes in the LOU\/M Wsl rat. Cancer Res. 1984;44:3698\u2013705.","journal-title":"Cancer Res"},{"key":"1588_CR14","doi-asserted-by":"crossref","unstructured":"Gabizon AA, Gabizon-Peretz S, Modaresahmadi S, La-Beck NM. Thirty years from FDA approval of pegylated liposomal doxorubicin (Doxil\/Caelyx): an updated analysis and future perspective. bmjonc [Internet]. 2025 [cited 2025 Feb 18];4. https:\/\/bmjoncology.bmj.com\/content\/4\/1\/e000573.","DOI":"10.1136\/bmjonc-2024-000573"},{"key":"1588_CR15","doi-asserted-by":"publisher","first-page":"1873","DOI":"10.1073\/pnas.78.3.1873","volume":"78","author":"EA Forssen","year":"1981","unstructured":"Forssen EA, T\u00f6k\u00e8s ZA. Use of anionic liposomes for the reduction of chronic doxorubicin-induced cardiotoxicity. Proc Natl Acad Sci USA. 1981;78:1873\u20137.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1588_CR16","doi-asserted-by":"publisher","first-page":"419","DOI":"10.2165\/00003088-200342050-00002","volume":"42","author":"A Gabizon","year":"2003","unstructured":"Gabizon A, Shmeeda H, Barenholz Y. Pharmacokinetics of pegylated liposomal doxorubicin. Clin Pharmacokinet. 2003;42:419\u201336.","journal-title":"Clin Pharmacokinet"},{"key":"1588_CR17","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/S0168-3659(99)00248-5","volume":"65","author":"H Maeda","year":"2000","unstructured":"Maeda H, Wu J, Sawa T, Matsumura Y, Hori K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release. 2000;65:271\u201384.","journal-title":"J Control Release"},{"key":"1588_CR18","doi-asserted-by":"publisher","first-page":"2412","DOI":"10.1158\/0008-5472.CAN-12-4561","volume":"73","author":"U Prabhakar","year":"2013","unstructured":"Prabhakar U, Maeda H, Jain RK, Sevick-Muraca EM, Zamboni W, Farokhzad OC, et al. Challenges and key considerations of the enhanced permeability and retention effect for nanomedicine drug delivery in oncology. Cancer Res. 2013;73:2412\u20137.","journal-title":"Cancer Res"},{"key":"1588_CR19","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1002\/(SICI)1097-0142(19990701)86:1<72::AID-CNCR12>3.0.CO;2-1","volume":"86","author":"Z Symon","year":"1999","unstructured":"Symon Z, Peyser A, Tzemach D, Lyass O, Sucher E, Shezen E, et al. Selective delivery of doxorubicin to patients with breast carcinoma metastases by stealth liposomes. Cancer. 1999;86:72\u20138.","journal-title":"Cancer"},{"key":"1588_CR20","first-page":"987","volume":"54","author":"A Gabizon","year":"1994","unstructured":"Gabizon A, Catane R, Uziely B, Kaufman B, Safra T, Cohen R, et al. Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes. Cancer Res. 1994;54:987\u201392.","journal-title":"Cancer Res"},{"key":"1588_CR21","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1038\/s41467-018-03705-y","volume":"9","author":"D Rosenblum","year":"2018","unstructured":"Rosenblum D, Joshi N, Tao W, Karp JM, Peer D. Progress and challenges towards targeted delivery of cancer therapeutics. Nat Commun. 2018;9:1410.","journal-title":"Nat Commun"},{"key":"1588_CR22","unstructured":"European Medicines Agency. Caelyx pegylated liposomal 2 mg\/ml concentrate for solution for infusion, Summary of product characteristics [Internet]. 2025 [cited 2025 Mar 17]. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/caelyx-pegylated-liposomal-epar-product-information_en.pdf. Accessed 30 Oct 2025."},{"key":"1588_CR23","doi-asserted-by":"publisher","first-page":"3312","DOI":"10.1200\/JCO.2001.19.14.3312","volume":"19","author":"AN Gordon","year":"2001","unstructured":"Gordon AN, Fleagle JT, Guthrie D, Parkin DE, Gore ME, Lacave AJ. Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. JCO. 2001;19:3312\u201322.","journal-title":"JCO"},{"key":"1588_CR24","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1016\/j.ejca.2005.12.011","volume":"42","author":"RE Coleman","year":"2006","unstructured":"Coleman RE, Biganzoli L, Canney P, Dirix L, Mauriac L, Chollet P, et al. A randomised phase II study of two different schedules of pegylated liposomal doxorubicin in metastatic breast cancer (EORTC-10993). Eur J Cancer. 2006;42:882\u20137.","journal-title":"Eur J Cancer"},{"key":"1588_CR25","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1186\/1471-2407-11-373","volume":"11","author":"M Fiegl","year":"2011","unstructured":"Fiegl M, Mlineritsch B, Hubalek M, Bartsch R, Pluschnig U, Steger GG. Single-agent pegylated liposomal doxorubicin (PLD) in the treatment of metastatic breast cancer: results of an Austrian observational trial. BMC Cancer. 2011;11:373.","journal-title":"BMC Cancer"},{"key":"1588_CR26","doi-asserted-by":"publisher","first-page":"3893","DOI":"10.1200\/JCO.2004.08.157","volume":"22","author":"AM Keller","year":"2004","unstructured":"Keller AM, Mennel RG, Georgoulias VA, Nabholtz J-M, Erazo A, Lluch A, et al. Randomized phase III trial of pegylated liposomal doxorubicin versus vinorelbine or mitomycin C plus vinblastine in women with taxane-refractory advanced breast cancer. JCO. 2004;22:3893\u2013901.","journal-title":"JCO"},{"key":"1588_CR27","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/0005-2736(92)90136-A","volume":"1104","author":"D Liu","year":"1992","unstructured":"Liu D, Mori A, Huang L. Role of liposome size and RES blockade in controlling biodistribution and tumor uptake of GM1-containing liposomes. Biochim Biophys Acta (BBA) Biomembr. 1992;1104:95\u2013101.","journal-title":"Biochim Biophys Acta (BBA) Biomembr"},{"key":"1588_CR28","doi-asserted-by":"publisher","first-page":"319","DOI":"10.7150\/thno.18078","volume":"7","author":"X Sun","year":"2017","unstructured":"Sun X, Yan X, Jacobson O, Sun W, Wang Z, Tong X, et al. Improved tumor uptake by optimizing liposome based RES blockade strategy. Theranostics. 2017;7:319\u201328.","journal-title":"Theranostics"},{"key":"1588_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2024.113588","volume":"201","author":"I Colombo","year":"2024","unstructured":"Colombo I, Koster K-L, Holer L, Haefliger S, Rabaglio M, Bastian S, et al. TLD-1, a novel liposomal doxorubicin, in patients with advanced solid tumors: dose escalation and expansion part of a multicenter open-label phase I trial (SAKK 65\/16). Eur J Cancer. 2024;201:113588.","journal-title":"Eur J Cancer"},{"key":"1588_CR30","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1007\/s00280-024-04679-z","volume":"94","author":"AM Mc Laughlin","year":"2024","unstructured":"Mc Laughlin AM, Hess D, Michelet R, Colombo I, Haefliger S, Bastian S, et al. Population pharmacokinetics of TLD-1, a novel liposomal doxorubicin, in a phase I trial. Cancer Chemother Pharmacol. 2024;94:349\u201360.","journal-title":"Cancer Chemother Pharmacol"},{"key":"1588_CR31","unstructured":"Swiss Group for Clinical Cancer Research. TLD-1, a Novel Liposomal Doxorubicin, in Patients With Advanced Solid Tumors: A Multicenter Open-label Single-arm Phase I Trial [Internet]. clinicaltrials.gov; 2024 Nov. Report No.: NCT03387917. https:\/\/clinicaltrials.gov\/study\/NCT03387917. Accessed 30 Oct 2025."},{"key":"1588_CR32","unstructured":"R Core Team. R: a language and environment for statistical computing [Internet]. Vienna, Austria: R Foundation for Statistical Computing; 2023. https:\/\/www.R-project.org\/. Accessed 30 Oct 2025."},{"issue":"11\u2013107","key":"1588_CR33","first-page":"S65","volume":"42","author":"WS Denney","year":"2015","unstructured":"Denney WS, Duvvuri S, Buckeridge C. Simple, automatic noncompartmental analysis: The PKNCA R package. J Pharmacokinet Pharmacodyn. 2015;42(11\u2013107):S65.","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"1588_CR34","unstructured":"European Medicines Agency. Pegylated liposomal doxorubicin hydrochloride concentrate for solution 2 mg\/ml product-specific bioequivalence guidance. 2019. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/pegylated-liposomal-doxorubicin-hydrochloride-concentrate-solution-2-mgml-product-specific-bioequivalence-guidance_en.pdf. Accessed 30 Oct 2025."},{"key":"1588_CR35","unstructured":"U.S. Department of Health and Human Services. Common Terminology Criteria for Adverse Events (CTCAE) v.5.0. 2017. Available from: https:\/\/dctd.cancer.gov\/research\/ctep-trials\/for-sites\/adverse-events\/ctcae-v5-5x7.pdf. Accessed 30 Oct 2025."},{"key":"1588_CR36","doi-asserted-by":"publisher","DOI":"10.1136\/bmjonc-2024-000573","volume":"4","author":"AA Gabizon","year":"2025","unstructured":"Gabizon AA, Gabizon-Peretz S, Modaresahmadi S, La-Beck NM. Thirty years from FDA approval of pegylated liposomal doxorubicin (Doxil\/Caelyx): an updated analysis and future perspective. bmjonc. 2025;4:e000573.","journal-title":"bmjonc"},{"key":"1588_CR37","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.jconrel.2023.05.027","volume":"359","author":"Z Lin","year":"2023","unstructured":"Lin Z, Deng T, Liu Y, Zheng S, Wang G, He H, et al. Comprehensive analysis of the influence of physicochemical properties and tumor-associated environments on liposome intratumoral penetration. J Control Release. 2023;359:33\u201351.","journal-title":"J Control Release"},{"key":"1588_CR38","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2020.120012","volume":"592","author":"H Popilski","year":"2021","unstructured":"Popilski H, Feinshtein V, Kleiman S, Mattarei A, Garofalo M, Salmaso S, et al. Doxorubicin liposomes cell penetration enhancement and its potential drawbacks for the tumor targeting efficiency. Int J Pharm. 2021;592:120012.","journal-title":"Int J Pharm"},{"key":"1588_CR39","doi-asserted-by":"publisher","DOI":"10.1016\/j.rsurfi.2025.100473","volume":"19","author":"M Ahmad","year":"2025","unstructured":"Ahmad M, Mustafa G, Abdel-Wahab B, Pathak K, Das A, Sahariah JJ, et al. From bench to bedside: advancing liposomal doxorubicin for targeted cancer therapy. Results Surf Interfaces. 2025;19:100473.","journal-title":"Results Surf Interfaces"},{"key":"1588_CR40","doi-asserted-by":"publisher","first-page":"643","DOI":"10.4155\/tde.11.19","volume":"2","author":"JA Y\u00e1\u00f1ez","year":"2011","unstructured":"Y\u00e1\u00f1ez JA, Remsberg CM, Sayre CL, Forrest ML, Davies NM. Flip-flop pharmacokinetics\u2014delivering a reversal of disposition: challenges and opportunities during drug development. Ther Deliv. 2011;2:643\u201372.","journal-title":"Ther Deliv"},{"key":"1588_CR41","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1111\/j.1365-2885.2004.00600.x","volume":"27","author":"PL Toutain","year":"2004","unstructured":"Toutain PL, Bousquet-M\u00e9lou A. Plasma terminal half-life. J Vet Pharmacol Ther. 2004;27:427\u201339.","journal-title":"J Vet Pharmacol Ther"},{"key":"1588_CR42","unstructured":"InnoMedica Holding AG. Data on File. 2025."},{"key":"1588_CR43","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1007\/s10549-016-4033-3","volume":"161","author":"N Harbeck","year":"2017","unstructured":"Harbeck N, Saupe S, J\u00e4ger E, Schmidt M, Kreienberg R, M\u00fcller L, et al. A randomized phase III study evaluating pegylated liposomal doxorubicin versus capecitabine as first-line therapy for metastatic breast cancer: results of the PELICAN study. Breast Cancer Res Treat. 2017;161:63\u201372.","journal-title":"Breast Cancer Res Treat"},{"key":"1588_CR44","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.1038\/sj.bjc.6603158","volume":"94","author":"S-E Al-Batran","year":"2006","unstructured":"Al-Batran S-E, Bischoff J, von Minckwitz G, Atmaca A, Kleeberg U, Meuthen I, et al. The clinical benefit of pegylated liposomal doxorubicin in patients with metastatic breast cancer previously treated with conventional anthracyclines: a multicentre phase II trial. Br J Cancer. 2006;94:1615\u201320.","journal-title":"Br J Cancer"},{"key":"1588_CR45","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/1471-2407-10-2","volume":"10","author":"J Huober","year":"2010","unstructured":"Huober J, Fett W, Nusch A, Neise M, Schmidt M, Wischnik A, et al. A multicentric observational trial of pegylated liposomal doxorubicin for metastatic breast cancer. BMC Cancer. 2010;10:2.","journal-title":"BMC Cancer"},{"key":"1588_CR46","unstructured":"European Medicines Agency. Investigation of bioequivalence\u2014scientific guideline [Internet]. 2010 [cited 2024 Nov 28]. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-investigation-bioequivalence-rev1_en.pdf. Accessed 30 Oct 2025."},{"key":"1588_CR47","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1111\/ajco.13776","volume":"19","author":"J Methaneethorn","year":"2023","unstructured":"Methaneethorn J, Tengcharoen K, Leelakanok N, AlEjielat R. Population pharmacokinetics of doxorubicin: a systematic review. Asia Pac J Clin Oncol. 2023;19:9\u201326.","journal-title":"Asia Pac J Clin Oncol"}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-025-01588-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40262-025-01588-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-025-01588-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T10:47:46Z","timestamp":1770374866000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40262-025-01588-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,18]]},"references-count":47,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["1588"],"URL":"https:\/\/doi.org\/10.1007\/s40262-025-01588-z","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"value":"0312-5963","type":"print"},{"value":"1179-1926","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,18]]},"assertion":[{"value":"15 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ilaria Colombo: declares institutional funding for clinical trials as PI from AstraZeneca, Merck Sharp & Dhome, Vivesto, Tolremo, Orion, Bayer, lncyte, Debio; consultancy\/advisor role from AstraZeneca, GlaxoSmithKline, Merck Sharp & Dhome, AbbVie, Biontech, lncyte, Beigene outside the submitted work; Kira-Lee Koster: support for attending meetings and travel (paid to institution) from Takeda Pharma and Janssen-Cilag; Anna M. Mc Laughlin: current employee of Pharmetheus AB and a paid consultant to multiple pharmaceutical companies; Stefan Halbherr: Stefan Halbherr owns shares of InnoMedica Holding AG and functions as part of the executive management of the firm; Anastasios Stathis: Institutional funding for clinical trials: Innomedica, Abbvie; ADC Therapeutics; Amgen, Astra Zeneca; Bayer; Cellestia; Incyte, Loxo Oncology; Merck MSD; Novartis; Pfizer; Philogen; Roche. Consultant\/expert testimony\/advisory board (institutional): Debiopharm, Janssen, AstraZeneca, Incyte, Eli Lilly, Novartis, Roche, Loxo Oncology. Travel grant: Incyte; Astra Zeneca. Charlotte Kloft: research grants from an industry consortium (AbbVie Deutschland GmbH & Co. K.G., AstraZeneca, Boehringer Ingelheim Pharma GmbH & Co. KG., Gruenenthal GmbH, F. Hoffmann- La Roche Ltd., Merck KGaA, Novo Nordisk A\/S and Sanofi) for the graduate research training program PharMetrX, from the Innovative Medicines Initiative-Joint Undertaking (\u201cDDMoRe\u201d), from H2020- EU.3.1.3 (\u201cFAIR\u201d), Diurnal Ltd. and the Federal Ministry of Education and Research within the Joint Programming Initiative on Antimicrobial Resistance Initiative (\u201cJPIAMR\u201d), all outside the submitted work; Markus Joerger: advisory role (institutional): Novartis, Astra Zeneca, Basilea Pharmaceutica, Bayer, BMS, Debiopharm, MSD, Roche, Sanofi; research funding: Swiss Cancer Research; travel grants: Roche, Sanofi, Takeda. All other authors declare no competing interests for this work.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Conceptualization: Marian Klose, Ilaria Colombo, Katrin Gobat, Kira-Lee Koster, Simon Haefliger, Manuela Rabaglio, Sara Bastian, Michael Schwitter, Ursina Z\u00fcrrer-H\u00e4rdi, Katrin Eckhardt, Stefanie Hayoz, Stefan Halbherr, Cristiana Sessa, Robin Michelet, Anna M. Mc Laughlin, Dagmar Hess, Anastasios Stathis, Charlotte Kloft, Markus Joerger; data curation: Marian Klose, Ilaria Colombo, Katrin Gobat, Kira-Lee Koster, Simon Haefliger, Manuela Rabaglio, Sara Bastian, Michael Schwitter, Ursina Z\u00fcrrer-H\u00e4rdi, Katrin Eckhardt, Cristiana Sessa, Robin Michelet, Anna M. Mc Laughlin, Dagmar Hess, Anastasios Stathis, Charlotte Kloft, Markus Joerger; formal analysis: Marian Klose, Ilaria Colombo, Katrin Gobat, Katrin Eckhardt, Stefanie Hayoz, Robin Michelet, Anna M. Mc Laughlin, Charlotte Kloft, Markus Joerger; funding acquisition: Stefan Halbherr; investigation: Ilaria Colombo, Kira-Lee Koster, Simon Haefliger, Manuela Rabaglio, Sara Bastian, Michael Schwitter, Ursina Z\u00fcrrer-H\u00e4rdi, Cristiana Sessa, Dagmar Hess, Anastasios Stathis, Markus Joerger; methodology: Marian Klose, Ilaria Colombo, Katrin Gobat, Katrin Eckhardt, Stefanie Hayoz, Robin Michelet, Anna M. Mc Laughlin, Anastasios Stathis, Charlotte Kloft, Markus Joerger; project administration: Marian Klose, Ilaria Colombo, Katrin Gobat, Katrin Eckhardt, Stefanie Hayoz, Dagmar Hess, Anastasios Stathis, Charlotte Kloft, Markus Joerger; resources: Stefan Halbherr; software: Marian Klose, Katrin Gobat, Katrin Eckhardt, Stefanie Hayoz, Robin Michelet, Anna M. Mc Laughlin, Charlotte Kloft, Markus Joerger; supervision: Katrin Eckhardt, Dagmar Hess, Charlotte Kloft, Markus Joerger; validation: Marian Klose, Ilaria Colombo, Katrin Gobat, Katrin Eckhardt, Stefanie Hayoz, Robin Michelet, Anna M. Mc Laughlin, Markus Joerger; visualization: Marian Klose, Ilaria Colombo, Katrin Gobat, Katrin Eckhardt, Stefanie Hayoz, Robin Michelet, Anna M. Mc Laughlin, Charlotte Kloft, Markus Joerger; writing \u2013 original draft: Marian Klose, Ilaria Colombo, Katrin Gobat, Markus Joerger; writing \u2013 review & editing: Marian Klose, Ilaria Colombo, Katrin Gobat, Kira-Lee Koster, Simon Haefliger, Manuela Rabaglio, Sara Bastian, Michael Schwitter, Ursina Z\u00fcrrer-H\u00e4rdi, Katrin Eckhardt, Stefanie Hayoz, Stefan Halbherr, Cristiana Sessa, Robin Michelet, Anna M. Mc Laughlin, Dagmar Hess, Anastasios Stathis, Charlotte Kloft, Markus Joerger.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 contributions"}},{"value":"The study was approved by the ethics committees of the participating institutions (lead ethics committee: Ethikkommission Ostschweiz; also: Kantonale Ethikkommission Bern, Ethikkommission Nordwest- und Zentralschweiz, Ethikkommission Tessin, and Ethikkommission Z\u00fcrich), and by the relevant regulatory authorities (Swissmedic). All participants provided written informed consent prior to inclusion in the study. The study was conducted in accordance with the ethical standards laid down in the Declaration of Helsinki, as well as in compliance with Good Clinical Practice guidelines.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The data of this study can be obtained from the corresponding author upon reasonable request.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability statement"}},{"value":"The source code supporting theresults of this study can be made available upon reasonable request.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}}]}}